Cham BE (2022) The Pharmacology of Curaderm in the Treatment of Basal Cell Carcinoma. Clin Med Rev Case Rep 9:399.

Research Article | OPEN ACCESS DOI: 10.23937/2378-3656/1410399

The Pharmacology of Curaderm in the Treatment of Basal Cell Carcinoma

B E Cham*

Australasian Medical Research, Port Vila, Republic of Vanuatu


Skin cancer is the most common form of cancer in the United States of America and in Australia. Basal cell carcinoma (BCC), the most prominent skin cancer, is curable, but can be disfiguring and costly to treat.

Treatment of BCC is important, because untreated tumours can grow incessantly and invade underlying tissue. Surgery has the highest cure rate for BCC. Other effective treatments for BCC include radiation therapy, laser therapy, electrosurgery, cryotherapy, fluorouracil and imiquimod therapies. All of these skin cancer therapies are indiscriminate with necrotic, unregulated, chaotic cell death sequelae.

Lack of selectivity and specificity with resulting necrosis restrict these therapies, as evidenced by scarring, recurrence of the treated lesion and limited cosmetic outcomes. Curaderm is a selective drug that has the ability to discriminate between skin cancer cells and normal skin cells. Furthermore, Curaderm is highly specific and is capable of causing cancer cell death by the orderly process of apoptosis.

The clinical aspects of Curaderm pharmacotherapy have amply been described in the literature. Recently, a thought-provoking article "Curaderm, the long-awaited breakthrough for basal cell carcinoma" was published. Although the article is awe- inspiring, it does not address the mechanisms and mode of actions of Curaderm that achieve such remarkable clinical outcomes.

This communication centres on the pharmacological mechanisms, which establish that Curaderm is indeed both selective and specific in eliminating basal cell carcinoma from the skin.


Cancer, Curaderm, BEC, Solamargine, Apoptosis, BCC, Basal cell carcinoma, Skin cancer


BCC is the most common form of skin cancer and the most frequently occurring form of all cancers in humans. An estimated 3.6 million cases are diagnosed each year in the U.S. and this number is steadily increasing.

BCC most often occurs when DNA damage from over-exposure to ultraviolet (UV) radiation from the sun triggers undesirable changes in the basal cells in the outermost layer of the skin. This can result in uncontrolled growth of the affected basal cells leading to BCC.

Treatments of BCC may involve:

• Surgical removal consisting of excision, Mohs surgery or curettage and electrodesiccation

• Cryotherapy

• Radiation

• Photodynamic therapy

• Imiquimod

• 5-Fluorouracil

When found early and treated by the above procedures, the BCC can often be removed. However, depending on the procedure used, because of the non-selectivity and non-specificity of the treatment procedure, the recurrence rate of the BCC can be high and the cosmetic outcome suboptimal.

Because of lack of selectivity and specificity, virtually all of the above treatments are indiscriminate in their actions and result in necrosis of cancer cells, including normal cells.

Curaderm is a topical treatment for BCC that contains natural allelochemical secondary metabolic glycoalkaloids with robust anticancer properties [1,2].

Curaderm contains BEC, which is a mixture of tri-, di-, and mono-glycosides of solasodine. The triglycoside solamargine is the most effective anticancer component and represents 86% of total anticancer activity [1,3,4]. Solamargine, a small-molecule drug, is a triglycoside of which the alkaloid solasodine is conjugated with two molecules of the plant sugar rhamnose and one molecule glucose.

Cell culture, animal and human studies have determined the efficacy of BEC and its individual components with high therapeutic indices for a wide variety of cancers [1-27].

Recently, a thought-provoking review article described the clinical aspects of Curaderm, a solamargine containing topical cream treatment for BCC [1].

However, the pharmacology of Curaderm therapy was not addressed in the review article. To fully appreciate the safety, high efficacy and remarkable cosmetic results obtained with Curaderm therapy, it is important to understand the pharmacological aspects of selectivity, specificity and mode of cancer cell death.


Solamargine in Curaderm, through its rhamnose content (Figure 1 highlighted area) selectively identifies and binds to cancer cells.

Figure 1: Chemical structure of solamargine, the main anticancer ingredient in Curaderm. The rhamnose sugar moiety (highlighted area) selectively identifies and interacts with specific rhamnose binding proteins (RBP) that are located on the surface of cancer cells. View Figure 1

Cell culture and whole animal studies show conclusively that cancer cells contain specific endogenous endocytic lectins (EELs) [1-5]. These lectins have been identified and characterised as rhamnose binding proteins (RBP) and are located on the surface of cancer cells, whereas normal non-cancer cells lack these receptors. Rhamnose is a plant sugar and is normally not present in the human body.

RBP on cancer cells are mutant proteins that possess cancer cell-specific binding affinities with rhamnose and its conjugates. The number of RBP receptors on the various cancer cell types range from 500-10,000 per cell with an affinity constant of 1.5 x 10-5 M and a molecular weight of 67 kDa [4,6]. Different cell populations of specific cancers establish that a single type of RBP receptor is involved in virtually all cancer cell lines. There are two distinct binding categories of solamargine to cancer cells, which are related to receptor affinity and numbers of receptors per cell [4,6,28,29]. Cutaneous BCC, squamous cell carcinoma and malignant melanoma possess receptors with high affinity for solamargine.

Cellular, animal- and human cancer cell competitive inhibition studies of BEC with free, unbound rhamnose have established that free, unbound rhamnose interferes with the efficacy of solamargine. It is therefore essential to ensure the absence of free, unbound rhamnose in the BEC-containing formulations [1-5].

Fluorescence imaging analysis of a synthesized biotinylated-rhamnose probe has visualized the expression of RBP receptors on cancer cells but not normal cells (Figure 2) [29].

Figure 2: Identification of specific rhamnose binding protein (RBP) receptors on cancer cells by a fluorescence rhamnose probe. Normal non-cancer cells do not possess the RBP receptors. The red images indicate the binding of rhamnose conjugates (solamargine) to RBP receptors. View Figure 2

Using this technique, it was shown that very low concentrations of free rhamnose completely blocked the binding of the probes to cancer cells (Figure 3) [2-6] [29,30].

Figure 3: Confocal microscopic view of rhamnose-QD probe (representing solamargine) localized on the cell surface of human squamous cell carcinoma (KB) cells. The binding of the probe was blocked by rhamnose. Confocal microscope image of KB cells labelled by probe (red) and Hoechst stain (blue). View Figure 3

Indeed, at a clinical level the presence of free rhamnose imparts inhibitory properties to the efficacy of BEC or solamargine formulations when treating terminal tumours and skin cancers [4].

Specificity and Efficacy

After identification and binding of solamargine to its specific RBP receptor, solamargine is internalized into the cancer cell by receptor-mediated endocytosis through endosomes and ultimately in the lysosomes and mitochondria. Consequently, the moiety of the alkaloid solasodine (Figure 4, highlighted area) exerts apoptosis by increasing pro-apoptotic Bax and Bak proteins and decreasing the anti-apoptotic Bcl-2 and Bcl-x proteins at the transcriptional and translational phases. Caspase-9 and Caspase-3 are activated during these processes, resulting in apoptosis [2-4] [31-37].

Figure 4: After specific internalisation of solamargine (SM) by receptor-mediated endocytosis into the cancer cell, the alkaloid moiety solasodine (highlighted area) exerts apoptosis in the cancer cell. View Figure 4

Solamargine and BEC also induce the extrinsic apoptotic death pathway in cancer cells by up-regulating the expressions of external death receptors such as tumour necrosis factor receptor 1 (TNFR-1) and 6 (TNFRSF6 or Fas receptor), TNFR-1-associated death domain (TRADD) and Fas-associated death domain (FADD) [2-4] [31-37]. Figure 5 illustrates schematically the process of apoptosis.

Figure 5: Schematic representation of solamargine (SM)-induced apoptosis by identifiable anti cancer properties through a variety of biological pathways in the cancer cell. The cancer cell dies neatly, without damaging its neighbours. View Figure 5

The impressive sensitivity of selectivity of Curaderm towards malignant cancer cells is shown by studies whereby solamargine is able to clearly discriminate primary and metastatic melanoma cells from benign melanoma cells or normal non cancer cells, a remarkable feature (Figure 6) [6].

Figure 6: Flow cytometry analysis showed that solamargine (SM) increased cell death tenfold more in malignant to benign cells. 10 μM Solamargine treatment for 2 h selectively caused massive cellular death of WM115 primary and WM239 metastatic melanoma cells, which were at least tenfold, more than that detected in benign WM35 and/or in bovine aortic endothelial cells (BAEC) normal cells.
The top right quadrant of the figures indicates cell death. It is seen that solamargine (SM) kills 72.6% of primary melanoma cells and that no treatment kills only 0.3% of these cancer cells (top row). Similarly, SM kills 70% of metastatic melanoma and no treatment kills 1.6% of these cancer cells (second row). Importantly, SM does not significantly kill benign melanoma cells (untreated 2.1%, SM treated 7.3%) (Third row), nor does SM kill normal cells (untreated 3.2%, SM treated 5.8%) (Fourth row). View Figure 6

For a drug to be able to identify an undesirable cancer cell amongst normal cells is a major feat. But, for that drug to also be able to specifically kill the undesirable cancer cell and not affect surrounding normal cells is extraordinary. This is exactly what Curaderm does when treating cutaneous BCCs!

At a clinical level compelling evidence of selectivity and specificity of BEC towards cancer cells resulting in apoptosis occurs when treating skin cancers [1-4].

The BEC-containing cream formulation Curaderm seeks and destroys BCC cells by apoptosis whilst normal skin cells replace the dead cancer cells DURING therapy. This indicates that BEC only affects cancer cells and not normal cells. Curaderm locates and eliminates cancer cells at the microscopic level and also kills cancer cells not seen with the naked eye. Visually, during Curaderm therapy, the treated skin cancer lesion appears to initially become larger until the cancer cells are eliminated.

This is followed by reduction of skin lesion until complete removal of the skin cancer cells and replacement with normal cells occurs [1-4][7]. The ratio of cancer cell death by apoptosis and new normal skin cell growth determines the size of the visual observed lesion. This phenomenon reflects self-titration, whereby Curaderm treatment only ceases when the lesion is completely healed.

It is important to appreciate that whilst skin cancer cells are undergoing apoptosis during treatment with Curaderm, regeneration of new epidermis at the application site occurs. This phenomenon is supported by the preclinical and clinical observations that Curaderm is preferential in its action towards transformed cells and explains the impressive clinical and cosmetic outcomes [1-7].

These underlying unique pharmacological properties of Curaderm culminate in apoptosis and have led to the treatment of the various types of cutaneous BCCs, including superficial, nodular and infiltrating (morpheoic) BCCs. Moreover, BCCs that are located at difficult-to-treat areas are also very amenable to Curaderm therapy [1-4][7].

The following cases (Figure 7) show that because of selectivity, specificity, efficacy, cell death by apoptosis and autophagocytosis, Curaderm therapy for BCC is as good or even better than surgical excision, the considered gold standard method, for treating BCC [38-58].

Figure 7: Examples of poor treatment prognoses of BCC lesions due to size, type, depth, previous failure by other treatment modalities and location (column, Before Curaderm Treatment) and the impressive cosmetic outcomes of Curaderm therapy by simple topical application (column, After Curaderm Treatment). Curaderm-treated lesions did not recur for at least 5 years follow-up. View Figure 7

Safety of Curaderm

Curaderm contains 0.05 mg BEC/mL cream. Therapeutically, for large lesions less than 1 mL of Curaderm is applied to the treated lesion and two applications per day are recommended during treatment. Ripe eggplant fruits contain 20-50 mg BEC/kg fresh weight. An average eggplant fruit weighs approximately 300 g and contains approximately 15 mg of BEC.

This is more than 300 times the amount of BEC applied to the skin. In other words, the amount of BEC applied to the skin in the form of Curaderm is less than 1gram of extracted eggplant fruit!!!

Additionally, it was shown that 1 mg BEC/kg human body weight is safely administered intravenously into humans [2-8]. This translates to a person weighing 60 kg being able to tolerate 60 mg BEC in their blood.

This compares to a dose of BEC-1200 times more than is applied to the skin with Curaderm.

BEC concentrations in human plasma of 4000 ng/mL have been reported to be tolerable [8]. In Phases I-III using different concentrations of BEC in various cream formulations, no BEC could be detected in the plasma of the patients. The sensitivity of the HPLC-mass spectral analysis of BEC was 1 ng/mL plasma. This indicates that BEC in the cream formulations were safe by a factor of over 4000 [4].

All other ingredients in Curaderm, including salicylic acid and urea, have been, and are currently being used worldwide at much higher concentrations in over-the-counter (OTC) skin care products. The safety of the entire Curaderm formulation, including all ingredients, has been supported by biocompatibility studies [37].

A wide range of toxicological and pharmacological studies of BEC, including toxicokinetics, pharmacokinetics and pharmacodynamics, confirm the high efficacy and safety of Curaderm [2-5].


Curaderm therapy selectively, specifically, effectively and safely eliminates all types of BCC skin cancers by a process of apoptosis, culminating in excellent cosmetic outcomes. Curaderm is an ideal therapy for outpatient treatment.

Its limitation is the duration of therapy, which is dependent on the size, type, and location of the BCC. Transient local irritation due to the keratolytic agents in the formulation is mild to moderate, nevertheless, compliance is high and Curaderm is well tolerated. Recurrences of Curaderm-treated BCCs are very low. Curaderm has been available and is used by the public for over two decades with no reported serious adverse events. Curaderm is a thoroughly researched product and should be considered as a major additional treatment for BCC.


  1. Chase T, Cham KE, Cham BE (2020) Curaderm, the long-awaited breakthrough for basal cell carcinoma. Int J Clin Med 11: 579-604.
  2. Cham BE (2021) The evolution of curaderm which led to the revolution of skin cancer treatment.
  3. Cham A, Cham K, Chase T, Cham B (2015) A standardized plant extract containing a target compound is acceptable as a potent therapeutic entity: Relevance to BEC and solamargine, a topical clinical formulation curaderm BEC5. Journal of Cancer Treatment and Research 3: 22-27.
  4. Cham BE (2017) Solasodine, solamargine and mixtures of solasodine rhamnosides: Pathway to expansive clinical anticancer therapies. Int J Clin Med 8: 692-713.
  5. Cham BE (2013) Inspired by nature, proven by science. The new generation cancer treatment that causes cancer cells to commit suicide. Colorite Graphics.
  6. Al Sinani SS, Eltayeb EA, Coomber BL, Adham SA (2016) Solamargine triggers cellular necrosis selectively in different types of human melanoma cancer cells through extrinsic lysosomal mitochondrial death pathways. Cancer Cell Int 16: 287-294.
  7. Hu K, Kobayashi H, Dong A, Jing Y, Iwasaki S, et al. (1999) Antineoplastic agents III: Steroidal glycosides from solanum nigrum. Planta Med 65: 35-38.
  8. Cham BE (2013) Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents. Modern chemotherapy 2: 33-49.
  9. Cham BE (1994) Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacif J Pharmacol 9: 113-118.
  10. Vijayan P, Kumar SV, Dhanaraj SA, Badami S, Suresh B (2002) In vitro cytotoxicity and anti-tumor properties of the total alkaloid fraction of unripe fruits of Solanum pseudocapsicum. Pharmacology Biology 40: 456-460.
  11. Ono M, Nishimura K, Suzuki K, Fukushima T, Igoshi K, et al. (2006) Steroidal glycosides from the underground parts of solanum sodomaeum. Chem Pharm Bull 54: 230-233.
  12. Nakamura T, Komori C, Lee Y, Hashinoto F, Yahara S, et al. (1996) Cytotoxic activities of Solanum steroidal glycosides. Biol Pharm Bull 19: 564-566.
  13. Liu LF, Liang CH, Shiu LY, Lin WL, Lin CC, et al. (2004) Action of solamargine on human lung cancer cells-enhancement of the susceptibility of cancer cells to TNFs. FEBS Lett 577: 67-74.
  14. Lee KR, Kozukue N, Han JS, Park JH, Chang EY, et al. (2004) Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. J Agric Food Chem 52: 2832-2839.
  15. Kuo KW, Hsu SH, Li YP, Lin WL, Liu LF, et al. (2000) Anticancer activity evaluation of the Solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem Pharmacol 60: 1865-1873.
  16. Chang LC, Tsai TR, Wang JJ, Lin CN, Kuo KW (1998) The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis. Biochemical Biophysical Research Communications 242: 21-25.
  17. Badami S, Manohara Reddy SA, Kumar EP, Vijayan P, Suresh B (2003) Antitumor activity of total alkaloid fraction of Solanum pseudocapsicum leaves. Phytother Res 17: 1001-1004.
  18. Esteves-Souza A, Sarmento da Silva TM, Alves CCF, de Carvalho MG, Braz-Filho R (2002) Cytotoxic activities against ehrlich carcinoma, human K562 leukaemia of alkaloids and flavonoids from two solanum species. J Braz Chem Soc 13: 838-842.
  19. Chataing B, Christancho NB, Usubillaga A (1998) Topical treatment of herpes simplex, herpes zoster and genital herpes with a mixture of solanaceous glycoalkaloids. MedULA 7: 30-34.
  20. Chami LA, Méndez R, Chataing B, O’Callaghan J, Usubillaga A, et al. (2003) Toxicological effects of α- solamargine in experimental animals. Phytotherapy Research 17: 254-258.
  21. Hall CA, Hobby T, Cipollini M (2006) Efficacy and mechanisms of alpha-solasonine-and alpha-solamargine-induced cytolysis on two strains of trypanosoma cruzi. J Chem Ecol 32: 2405-2416.
  22. Verpoorte R (1998) Exploration of nature’s chemodiversity: The role of secondary metabolites as leads in drug development. Drug Discovery Today 3: 232-238.
  23. Roddick JG, Rÿrenber AL, Weissenber M (1990) Membrane-disrupting properties of the steroidal glycoalkaloids solasonine and solamargine. Phyto Chemistry 29: 1513-1518.
  24. Munari CC, de Oliveira PF, Campos JCL, Martins SPL, Da Costa JC, et al. (2014) Antiproliferative activity of solanum lycocarpum alkaloidal extract and their constituents, solamargine and solasonine, in tumor cell lines. J Nat Med 68: 236-241.
  25. Xu XH, Zhang L, Wu GS, Chen X, Li T, et al. (2017) Solasodine induces apoptosis, affects autophagy, and attenuates metastasis in ovarian cancer cells. Planta Medica 83: 254-260.
  26. Yu S, Sheu HM, Lee CH (2017) Solanum incanum extract (SR-T100) induces melanoma cell apoptosis and inhibits established lung metastasis. Oncotarget 8: 103509-103517.
  27. (2005) Pre-IND Submission 5. Solbec Pharmaceut.
  28. Lipscombe RJ, Carter SJ, Ruane M (2005) Rhamnose binding protein.
  29. Wang Y, Gao J, Gu G, Li G, Cui C, et al. (2011) In situ RBL receptor visualization and its mediated anticancer activity for solasodine rhamnosides. Chem Bio Chem 12: 2418-2420.
  30. Cham BE (2000) Medicinal compositions and their method of preparation.
  31. Shen KH, Hung JH, Chang CW, Weng YT, Wu MJ, et al. (2017) Solasodine inhibits invasion of human lung cancer cell through downregulation of miR-21 and MMP expression. Chem Biol Interact 268: 129-135.
  32. Zhuang Y, Wu C, Zhou J, Chen X, Wu J, et al. (2017) Solasodine inhibits human colorectal cancer cells through suppression of AKT/glycogen synthase kinase-3 β/β-catenin pathway. Cancer Sci 108: 2248-2264.
  33. Koduru S, Grierson DS, Venter M, Afolayan AJ (2007) Anticancer activity of steroid alkaloids isolated from Solanum aculeastrum. Pharm Biol 45: 613-618.
  34. Jayakumar K, Murugan K (2017) Purified solasodine and caulophyllumine: A from Solanum mauritianum Scop. Against MCF -7 breast cancer cell lines in terms of cell growth, cell cycle and apoptosis. J Pharmacogn Phytochem, 6: 472-478.
  35. Hameed A, Ijaz S, Mohammad IS, Muhammad KS, Akhtar N, et al. (2017) Aglycone solanidine and solasodine derivatives: A natural approach towards cancer. Biomed Pharmacother 94: 446-457.
  36. Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R (2008) Solasodine glycoalkaloids: A novel topical therapy for basal cell carcinoma. A double blind, randomized, placebo-controlled, parallel group, multicenter study. Internat J Dermatol 47: 78-82.
  37. Chase T, Cham KE, Cham BE (2020) Evaluation of dermal irritation and skin sensitization by curaderm. Int J Clin Med 11: 548-558.
  38. Cham BE, Meares HM (1987) Glycoalkaloids from Solanum sodomaeum are effective in the treatment of skin cancers in man. Cancer Letters 36: 111-118.
  39. Cham BE, Daunter B, Evans R (1991) Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Lett 59: 183-192.
  40. Cham BE (2013) A Review of solasodine rhamnosides therapy for in-situ squamous cell carcinoma on the Penis. Brit J Med & Medical Res 4: 621-631.
  41. Goldberg LH, Landau JM, Moody MN, Vergilis-Kalner IJ (2011) Treatment of bowen's disease on the penis with low concentrations of a standard mixture of solasodine glycosides and liquid nitrogen. Dermatol Surg 37: 858-861.
  42. Cham BE (2020) Combination treatment with BEC and cisplatin synergistically augments anticancer activity and results in increased absolute survival. Journal of Cancer Therapy 11: 470-482.
  43. Millward MM, Powell A, Daly P, Tyson S, Ferguson R. et al. (2006) Results of phase I clinical trials of coramsine in patients with advanced solid tumors. Journal of Clinical Oncology 24.
  44. Cham BE, Chase TR (2012) Solasodine rhamnosyl glycosides cause apoptosis in cancer cells, do they also prime the immune system resulting in long term protection against cancer? Planta Medica 78: 349-353.
  45. Cham BE (2007) Solasodine rhamnosyl glycosides specifically bind cancer cell receptors and induce apoptosis and necrosis. Treatment for skin cancer and hope for internal cancers. Res J Biol Sci 2: 503-514.
  46. Cham BE (2008) Cancer intralesion chemotherapy with solasodine rhamnosyl glycosides. Res J Biol Sci 3: 1008-1017.
  47. Cham BE (2007) Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large and troublesome skin cancers. Res J Biol Sci 2: 749-761.
  48. Cham BE (2011) Topical solasodine rhamnosyl glycosides derived from the eggplant treats large skin cancers: Two case reports. Int J Clin Med 2: 473-477.
  49. Chase TR (2011) CuradermBEC5 for skin cancers, is it? An overview. J Cancer Therapy 2: 728-745.
  50. Cham BE (2012) Intralesion and curaderm BEC5 topical combination therapies of solasodine rhamnosyl glycosides derived from the eggplant or devil’s apple result in rapid removal of large skin cancers. Methods of treatment compared. Int J Clin Med 3: 115-124.
  51. Cham BE (2013) Topical curadermBEC5 therapy for periocular nonmelanoma skin cancer: A review of clinical outcomes. Int J Clin Med 4: 233-238.
  52. Cham A, Cham BE (2015) Treatment of skin cancer with a selective apoptotic-inducing CuradermBEC5 topical cream containing solasodine rhamnosides. Int J Clin Med 6: 326-333.
  53. Cham BE, Cham K, Cham A, Chase T, Zhou V (2015) Treatment of non-melanoma skin cancers: An intra-comparison study of curadermBEC5 and various established modalities. J Cancer Therapy 6: 1045-1053.
  54. Dobrokhotova FZ, Betsev AF, Belysheva TS (2016) The use of Kuraderm drug in the treatment of basal cell carcinoma of the head and neck. Head and Neck Tumors 6: 22-26.
  55. Batsev AF, Dobrokhotova VZ, Cham BE (2016) Topical cream curadermBEC5 treats a recalcitrant basal cell carcinoma. Clin Med Rev Case Rep 3: 1-3.
  56. Cham BE (2020) First in man topical treatment of melanoma with solasodine glycosides in a formulation curaderm. J Cancer Therapy 11: 617-630.
  57. Daunter B, Cham BE (1990) Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Lett 55: 209-220.
  58. Yin S, Jin W, Qiu Y, Fu L, Wang T, et al. (2022) Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via LIF/miR-192-5p/CY61/Akt signaling pathway and eliciting immunostimulatory tumour microenvironment. J Hematol Oncol 15: 32.


Cham BE (2022) The Pharmacology of Curaderm in the Treatment of Basal Cell Carcinoma. Clin Med Rev Case Rep 9:399.